AstraZeneca entered into a multimillion-dollar licensing deal Monday giving it worldwide exclusive rights to develop and commercialize an oral therapy under development as a potential treatment for chronic obstructive pulmonary disease (COPD) and other inflammatory and respiratory diseases.
Under the financial terms of the deal, AstraZeneca (NYSE: AZN) will make an upfront payment of $2 million to C4X Discovery Holdings (AIM: C4XD), a drug discovery company with offices in Manchester and London,…
